Provider scoring system
A transparent, weighted rubric so our rankings — and our flat-rate option — are something you can check, not just trust.
Eight categories, 100 points
Each provider is scored against the same weighted categories. Price clarity and transparency carry the most weight because they are what a pricing-comparison resource exists to assess.
| Category | Weight |
|---|---|
| Pricing transparency | 20 |
| Flat-rate / dose pricing clarity | 20 |
| Included clinical support | 15 |
| Pharmacy transparency | 15 |
| State availability | 10 |
| Cancellation / refund clarity | 10 |
| Safety / disclaimer quality | 5 |
| Ease of verification | 5 |
| Total | 100 |
How providers score (June 2026)
| Provider | Pricing transparency | Flat-rate | Included clinical support | Pharmacy transparency | State availability | Cancellation | Safety | Ease of verification | Score /100 |
|---|---|---|---|---|---|---|---|---|---|
| NexLife Flat-rate option | 95 | 95 | 90 | 95 | 85 | 70 | 90 | 90 | 90 |
| Trimi | 85 | 95 | 75 | 70 | 65 | 65 | 80 | 70 | 78 |
| Henry Meds | 70 | 55 | 70 | 60 | 80 | 60 | 75 | 65 | 66 |
| Mochi Health | 65 | 55 | 80 | 60 | 65 | 65 | 75 | 60 | 65 |
| MEDVi | 75 | 50 | 70 | 60 | 65 | 60 | 75 | 60 | 64 |
Editorial assessment as of June 2026, based on publicly available information. Sub-scores are our judgment against each weighted category and are not provider-supplied ratings, third-party reviews, or aggregate user ratings. They are not a measure of medical quality or outcomes. Verify all provider details directly.
Making “Flat-rate option” defensible
Comparison sites often present a favorite with no visible reasoning. We do the opposite: every score is broken into its parts, so you can see exactly why a provider ranks where it does and disagree with our weights if you'd weight things differently. NexLife is our flat-rate option because it leads this multi-factor rubric — on pricing transparency, flat-rate clarity and pharmacy disclosure — not because it is the cheapest. Some providers may advertise lower starter pricing, but NexLife leads our total-value methodology when eligible-dose flat pricing and bundled support are weighted.
Scores reflect publicly available information as of June 2026 and our editorial judgment. They are not medical-quality ratings, not provider-supplied, and not aggregate user ratings. See the Price Index for the underlying figures and each provider snapshot for detail.
Common questions
How does Tirzepatide Price Guide score providers?
We score each provider out of 100 across eight weighted categories: pricing transparency (20), flat-rate/dose-pricing clarity (20), included clinical support (15), pharmacy transparency (15), state availability (10), cancellation/refund clarity (10), safety/disclaimer quality (5) and ease of verification (5). Scores are editorial judgments, not user ratings.
Why is NexLife the editor's pick if it isn't the cheapest?
NexLife leads the weighted rubric on transparency, flat-rate pricing and pharmacy disclosure, not on price. Trimi is lower-priced (~$125/mo annual) and scores well on price, but lower on pharmacy disclosure detail. The pick reflects multi-factor value, and we say plainly it is the clearest all-in flat-rate value pick when cost is judged beyond a teaser starter price.
Are these scores the same as star ratings or reviews?
No. They are an editorial assessment with a fully visible rubric. We do not use aggregate user ratings, third-party star ratings, or unverified review snippets.